The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional systemic treatments to high-efficacy biologics and targeted oral agents has significantly expanded market value. Additionally, the launch of emerging therapies such as zasocitinib (Takeda/Nimbus Therapeutics), icotrokinra (JNJ-77242113 [Johnson & Johnson Innovative Medicine and Protagonist Therapeutics]), piclidenoson (CF101 [Can-Fite BioPharma]), ESK-001 (Alumis), SFA-002 (SFA Therapeutics), and others further boost the market.
LAS VEGAS, Jan. 7, 2026 /PRNewswire/ -- DelveInsight's Psoriasis Market Insights report includes a comprehensive understanding of current treatment practices, psoriasis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Psoriasis Market Summary
- The market size for psoriasis was found to be USD 33.4 billion in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] in 2024.
- The United States accounted for the largest psoriasis treatment market size, approximately 80% of the total market size in the 7MM in 2024, compared to other major markets, including the EU4 countries, the United Kingdom, and Japan.
- Topical corticosteroids remain the most commonly used treatment for psoriasis, with BRYHALI offering extended use up to eight weeks and maintaining clinical relevance ahead of its 2026 loss of exclusivity.
- Among foam formulations, ENSTILAR stands out for its vitamin D analog base compared to SORILUX and LEXETTE. The recent approval of VTAMA in Japan marks a major milestone, as it becomes the first topical therapy for plaque psoriasis in that market, positioning it for strong uptake.
- The total number of diagnosed prevalent cases of psoriasis in the 7MM was ~16 million in 2024.
- Leading psoriasis companies, such as Takeda, Nimbus Therapeutics, Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, Can-Fite BioPharma, Alumis, SFA Therapeutics, and others, are developing new psoriasis treatment drugs that can be available in the psoriasis market in the coming years.
- The promising psoriasis therapies in clinical trials include Zasocitinib (TAK-279), Icotrokinra (JNJ-77242113), Piclidenoson (CF101), ESK-001, SFA-002, and others.
Discover the new psoriasis treatment @ Psoriasis Treatment Market
Key Factors Driving the Growth of the Psoriasis Market
Rising Psoriasis Disease Prevalence
The global prevalence of psoriasis is increasing, with approximately 125 million people affected worldwide. The total number of diagnosed prevalent psoriasis cases in the 7MM was 16 million in 2024. These cases are expected to increase during the forecast period (2025-2034), driven by rising awareness following the launch of emerging therapies, a growing geriatric population, and advancements in diagnostic approaches, particularly in pathophysiology and biomarker data.
Advancements in Biologic Psoriasis Therapies
Innovations in biologic treatments, Tumor necrosis factor-alpha (TNF-a) inhibitors (including ENBREL, REMICADE, and HUMIRA), IL-23 inhibitors (like TREMFYA, SKYRIZI, and ILUMYA), IL-17 inhibitors (such as COSENTYX, TALTZ, and SILIQ ), and others are revolutionizing psoriasis care.
Rising Psoriasis Clinical Trial Landscape
The emerging landscape holds a diverse range of therapeutic alternatives for psoriasis treatment, including zasocitinib (Takeda/Nimbus Therapeutics), icotrokinra (JNJ-77242113 [Johnson & Johnson Innovative Medicine and Protagonist Therapeutics]), piclidenoson (CF101 [Can-Fite BioPharma]), ESK-001 (Alumis), SFA-002 (SFA Therapeutics), and others. The expected launch of these therapies is expected to further positively impact the psoriasis market.
Emerging Oral Psoriasis Therapies in Development
Current emerging psoriasis drugs, including zasocitinib, ESK-001, piclidenoson, SFA-002, and icotrokinra, are mainly oral therapies, offering a potent alternative to injectable biologics and meeting patients' demand for convenience without compromising efficacy.
Promise of Takeda/Nimbus Therapeutics' Zasocitinib
Zasocitinib, a TYK2 inhibitor in Phase III trials, shows promise with its high efficacy and favorable safety profile compared to traditional JAK inhibitors. With up to one-third of patients achieving complete clearance, it represents a new frontier in oral psoriasis treatment.
Psoriasis Market Analysis
The psoriasis treatment landscape is evolving rapidly, driven by the steady introduction of innovative therapies. These newer agents deliver impressive clinical efficacy, each distinguished by specific mechanisms and safety profiles, making meaningful disease control attainable for nearly all patients who pursue treatment.
Tumor necrosis factor-alpha (TNF-a) inhibitors, such as ENBREL, REMICADE, and HUMIRA, were the earliest biologics approved for moderate-to-severe psoriasis. CIMZIA marked a strategic advancement as the first FDA-approved Fc-free biologic for adults with moderate-to-severe plaque psoriasis. Despite their effectiveness, TNF-a inhibitors have been linked to paradoxical reactions, including the onset of new psoriasis or exacerbation of previously inactive disease.
IL-23 inhibitors, including TREMFYA, SKYRIZI, and ILUMYA, are recognized for their favorable tolerability and well-established long-term safety. In contrast, IL-17 inhibitors such as COSENTYX, TALTZ, and SILIQ have shown more rapid skin clearance compared with IL-23 therapies.
Clinical evidence indicates that patients with plaque psoriasis who transition to SKYRIZI after insufficient response to COSENTYX or ILUMYA experience meaningful reductions in disease severity, improved symptom control, and enhanced quality of life.
Looking ahead, Amgen's leading psoriasis therapies, ENBREL and OTEZLA, are expected to face pressure from the Inflation Reduction Act, with Medicare price negotiations beginning for ENBREL in 2026 and for OTEZLA in 2027.
Psoriasis Competitive Landscape
The emerging landscape is vast and diverse. The major therapies anticipated to enter and compete, such as ESK-001 and zasocitinib (TYK2 inhibitors). Companies like Can-Fite BioPharma (piclidenoson; A3 Adenosine Receptor [A3AR] agonist) and SFA Therapeutics (SFA-002; TNF-a, IL-23, IL-10, IL-12, IL-17, and IFN-? inhibitor) are conducting late-stage trials for the treatment of psoriasis. With unique MoAs, these therapies hold an opportunity to stand out.
Takeda's TAK-279 is a late-stage, orally administered, highly selective allosteric inhibitor of TYK2, exhibiting roughly 1.3 million-fold greater selectivity for TYK2 over JAK1. In a Phase IIb trial involving patients with moderate-to-severe psoriasis, significantly higher proportions of patients treated with TAK-279 achieved PASI 75, PASI 90, and PASI 100 at doses of 5 mg, 15 mg, and 30 mg versus placebo at Week 12. The program has advanced into Phase III development, with a head-to-head trial against deucravacitinib expected to begin in 2025. According to Takeda's development roadmap, regulatory submission for zasocitinib is targeted for fiscal year 2026.
SFA Therapeutics' SFA-002 is a novel oral immunomodulatory agent being developed for autoimmune disorders, with an initial focus on mild-to-moderate chronic plaque psoriasis. Rather than inhibiting a single immune pathway, SFA-002 exerts a broad immunoregulatory effect by acting on multiple cellular mechanisms. It reduces the production of several key pro-inflammatory cytokines, including TNF-a, IL-23, IL-12, IL-17, IL-10, and IFN-?, while rebalancing the underlying autoimmune response.
Johnson & Johnson Innovative Medicine and Protagonist Therapeutics' Icotrokinra represents the first targeted oral peptide engineered to selectively inhibit the IL-23 receptor, a central driver of inflammation in moderate-to-severe plaque psoriasis, with potential applicability across other IL-23-mediated conditions. The compound binds the IL-23 receptor with single-digit picomolar affinity and demonstrates strong, highly selective suppression of IL-23 signaling in human T cells.
Alumis' ESK-001 is a next-generation investigational TYK2 inhibitor designed to address immune dysregulation across multiple inflammatory diseases driven by cytokines such as IL-23, IL-17, and type I interferons. Its selective mechanism aims to achieve robust pathway inhibition while minimizing off-target interactions and associated adverse effects.
The anticipated launch of these emerging therapies are poised to transform the psoriasis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the psoriasis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the psoriasis drugs @ Psoriasis Drugs Market
Recent Developments in the Psoriasis Market
- In September 2025, Johnson & Johnson announced that the US FDA had approved TREMFYA (guselkumab) for the treatment of children aged 6 years and older who weigh at least 40 kg with moderate to severe plaque psoriasis.
- In September 2025, Johnson & Johnson announced new data from the Phase III ICONIC-ADVANCE 1 and 2 studies, which assessed the superiority of icotrokinra over deucravacitinib in patients with moderate-to-severe plaque psoriasis.
- In May 2025, Arcutis Biotherapeutics announced that the Journal of the American Medical Association (JAMA) Dermatology published the positive results from a pivotal Phase III study evaluating the efficacy and safety of ZORYVE foam 0.3% as a once-daily monotherapy treatment for psoriasis of the scalp and body.
- In March 2025, SFA Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida.
- In March 2025, Boehringer Ingelheim presented new post-hoc exploratory analyses from the EFFISAYIL 2 clinical trial assessing the efficacy and safety of subcutaneous SPEVIGO in patients who have generalized pustular psoriasis at the AAD Annual Meeting 2025.
What is Psoriasis?
Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by the rapid buildup of skin cells, leading to thick, red, scaly patches that can be itchy, painful, or both. It occurs when the immune system mistakenly accelerates the life cycle of skin cells, causing them to accumulate on the skin's surface rather than shedding as usual. Psoriasis most commonly affects the elbows, knees, scalp, and lower back, but it can appear anywhere on the body. The condition is not contagious and tends to follow a relapsing-remitting course, with periods of flare-ups and remission. In addition to skin involvement, psoriasis may be associated with systemic inflammation and comorbidities, including psoriatic arthritis, cardiovascular disease, and metabolic disorders.
Psoriasis Epidemiology Segmentation
The psoriasis epidemiology section provides insights into the historical and current psoriasis patient pool and forecasted trends for the leading markets. Psoriasis is predominantly observed in adults, accounting for approximately 97% of all cases in the 7MM.
The psoriasis treatment market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
- Total Diagnosed Prevalent Cases of Psoriasis
- Type-specific Diagnosed Prevalent Cases of Psoriasis
- Location-specific Diagnosed Prevalent Cases of Psoriasis
- Severity-specific Diagnosed Prevalent Cases of Psoriasis
Psoriasis Market Report Metrics | Details |
Study Period | 2020-2034 |
Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
Psoriasis Market CAGR | 1.7 % |
Psoriasis Market Size in 2024 | USD 33.4 Billion |
Key Psoriasis Companies | Takeda, Nimbus Therapeutics, Johnson & Johnson Innovative Medicine, Protagonist Therapeutics, Can-Fite BioPharma, Alumis, SFA Therapeutics, Novartis, Sun Pharmaceutical, Dr Reddy's, Promius Pharma, Encore Dermatology, AbbVie, AstraZeneca, Bausch Health, Kyowa Kirin, LEO Pharma, UCB, LEO Pharma, Boehringer Ingelheim, Organon Pharmaceuticals, Eli Lilly and Company, Bristol Myers Squibb, Arcutis Biotherapeutics, Mayne Pharma, Bausch Health, MC2 Therapeutics, Almirall, and others |
Key Psoriasis Therapies | Zasocitinib (TAK-279), Icotrokinra (JNJ-77242113), Piclidenoson (CF101), ESK-001, SFA-002, COSENTYX, ILUMYA/ILUMETRI, BRYHALI, SERNIVO, SKYRIZI, TREMFYA, SILIQ/KYNTHEUM/LUMICEF, CIMZIA, ENSTILAR, SPEVIGO, VTAMA, TALTZ, SOTYKTU, ZORYVE, LEXETTE, DUOBRII, WYNZORA Cream, and others |
Scope of the Psoriasis Market Report
- Therapeutic Assessment: Psoriasis current marketed and emerging therapies
- Psoriasis Market Dynamics: Key Market Forecast Assumptions of Emerging Psoriasis Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Psoriasis Market Access and Reimbursement
Download the report to understand what is the latest research on psoriasis @ New Psoriasis Medication
Table of Contents
1 | Psoriasis Market Key Insights |
2 | Psoriasis Market Report Introduction |
3 | Executive Summary |
4 | Key Events |
5 | Epidemiology and Market Forecast Methodology |
6 | Psoriasis Market Overview at a Glance |
6.1 | Market Share (%) Distribution by Therapies of Psoriasis in 2020 |
6.2 | Market Share (%) Distribution by Therapies of Psoriasis in 2034 |
7 | Disease Background and Overview |
7.1 | Introduction |
7.2 | Causes and Risk Factors |
7.3 | Locations |
7.4 | Types of Psoriasis |
7.5 | Psoriasis Pathophysiology |
7.6 | Psoriasis Diagnosis |
7.7 | Treatment Guidelines |
8 | Epidemiology and Patient Population of 7MM |
8.1 | Key Findings |
8.2 | Assumption and Rationale |
8.3 | Total Diagnosed Prevalent Cases of Psoriasis in the 7MM |
8.4 | The United States |
8.4.1 | Total Diagnosed Prevalent Cases of Psoriasis in the US |
8.4.2 | Type-specific Diagnosed Prevalent Cases of Psoriasis in the US |
8.4.3 | Location-specific Diagnosed Prevalent Cases of Psoriasis in the US |
8.4.4 | Severity-specific Diagnosed Prevalent Cases of Psoriasis in the US |
8.5 | EU4 and the UK |
8.6 | Japan |
9 | Patient Journey of Psoriasis |
10 | Marketed Psoriasis Therapies |
10.1 | Key Cross of Marketed Therapies |
10.2 | BIMZELX (bimekizumab): UCB Pharma |
10.2.1 | Product Description |
10.2.2 | Regulatory Milestones |
10.2.3 | Other Developmental Activities |
10.2.4 | Clinical Development |
10.2.4.1 | Clinical Trial Information |
10.2.5 | Safety and Efficacy |
10.2.6 | Analyst View |
10.3 | COSENTYX (secukinumab): Novartis |
10.4 | ILUMYA/ILUMETRI (tildrakizumab-asmn): Sun Pharmaceutical/Almirall |
10.5 | BRYHALI (halobetasol propionate): Bausch Health |
10.6 | SERNIVO (betamethasone dipropionate): Dr Reddy's/Promius Pharma/Encore Dermatology |
10.7 | SKYRIZI (risankizumab-rzaa): AbbVie and Boehringer Ingelheim |
10.8 | TREMFYA (guselkumab): Johnson & Johnson |
10.9 | SILIQ/KYNTHEUM/LUMICEF (brodalumab): AstraZeneca/Bausch Health/Kyowa Kirin/LEO Pharma |
10.10 | CIMZIA (certolizumab pegol): UCB |
10.11 | ENSTILAR (calcipotriene and betamethasone dipropionate): LEO Pharma |
10.12 | SPEVIGO (spesolimab-sbzo): Boehringer Ingelheim |
10.13 | VTAMA (tapinarof): Organon Pharmaceuticals |
10.14 | TALTZ (ixekizumab): Eli Lilly and Company |
10.15 | SOTYKTU (deucravacitinib): Bristol Myers Squibb |
10.16 | ZORYVE (roflumilast): Arcutis Biotherapeutics |
10.17 | LEXETTE (Halobetasol Propionate Foam 0.05%): Mayne Pharma |
10.18 | DUOBRII (Halobetasol Propionate and Tazarotene Lotion): Bausch Health |
10.19 | WYNZORA Cream (calcipotriene and betamethasone dipropionate): MC2 Therapeutics/Almirall |
11 | Emerging Psoriasis Drugs |
11.1 | Key Cross Competition |
11.2 | Zasocitinib (TAK-279): Takeda/Nimbus Therapeutics |
11.2.1 | Product Description |
11.2.2 | Other Development Activity |
11.2.3 | Clinical Development |
11.2.3.1 | Clinical Trial Information |
11.2.4 | Safety and Efficacy |
11.2.5 | Analyst View |
11.3 | Icotrokinra (JNJ-77242113): Johnson & Johnson Innovative Medicine and Protagonist Therapeutics |
11.4 | Piclidenoson (CF101): Can-Fite BioPharma |
11.5 | ESK-001: Alumis |
11.6 | SFA-002: SFA Therapeutics |
12 | Psoriasis Market: 7MM Analysis |
12.1 | Key Findings |
12.2 | Psoriasis Market Outlook |
12.3 | Key Psoriasis Market Forecast Assumptions |
12.4 | Conjoint Analysis |
12.5 | Total Market Size of Psoriasis in the 7MM |
12.6 | Market Size of Psoriasis by Therapies in 7MM |
12.7 | United States Psoriasis Market Size |
12.7.1 | Total Market Size of Psoriasis in the United States |
12.7.2 | Market Size of Psoriasis by Therapies in the United States |
12.8 | EU4 and the United Kingdom Psoriasis Market Size |
12.9 | Japan Psoriasis Market Size |
13 | Psoriasis Market Unmet Needs |
14 | Psoriasis Market SWOT Analysis |
15 | KOL Views on Psoriasis |
16 | Psoriasis Market Access and Reimbursement |
16.1 | The United States |
16.2 | EU4 and the UK |
16.3 | Japan |
16.4 | Market Access and Reimbursement of Psoriasis |
17 | Bibliography |
18 | Psoriasis Market Report Methodology |
Related Reports
JAK Inhibitors Market
JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast - 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.
TNF-alpha Inhibitors Market
TNF-alpha Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast - 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TNF-alpha Inhibitors companies, including AbbVie, Amgen, Johnson & Johnson, Pfizer, UCB, Eli Lilly, Novartis, Merck, Sanofi, Boehringer Ingelheim, Samsung Bioepis, Celltrion, among others.
Interleukin-17 Inhibitors Market
Interleukin-17 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key IL-17 inhibitors companies, including MoonLake Immunotherapeutics, Affibody Medical AB, SFA Therapeutics, DICE Therapeutics, Eli Lilly, UCB Pharma, Novartis, AstraZeneca, Bausch Health, Kyowa Kirin, LEO Pharma, among others.
Psoriasis Clinical Trial Analysis
Psoriasis Pipeline Insight - 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriasis companies, including Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/psoriasis-market-to-exhibit-growth-at-a-cagr-of-1-7-during-the-forecast-period-20252034-owing-to-continuous-innovation-in-biologic-therapies-and-approval-of-oral-small-molecules--delveinsight-302654828.html
